Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Vet Med Sci ; 8(4): 1769-1779, 2022 07.
Article in English | MEDLINE | ID: mdl-35588498

ABSTRACT

Nanotechnology is a far-reaching technology with tremendous applications in various aspects, including general medicine, veterinary medicine, agriculture, aquaculture, and food production. Nanomaterials have exceptional physicochemical characteristics, including increased intestinal absorption, biodistribution, bioavailability, and improved antimicrobial and catalytic properties. Although nanotechnology is gaining ground in animal management, husbandry, and production, its wide use is still hampered by occasional toxicity and side effects. Zinc oxide nanoparticles (ZnO-NPs) have long been utilized in animal production, aquaculture, and pet animal medicine. However, the use ZnO-NPs in animals has been associated with reports of toxicity and side effects. ZnO-NPs may have shown numerous beneficial effects in animals; its use must be regulated with care to avoid unwanted consequences. Thus, this review emphasizes the usage of ZnO-NPs in animal production and laboratory animals and the potential side effects associated with the use of nanoparticles as a feed supplement and therapeutic compound.


Subject(s)
Nanoparticles , Zinc Oxide , Animals , Anti-Bacterial Agents , Biological Availability , Nanoparticles/toxicity , Tissue Distribution , Zinc Oxide/toxicity
2.
Int J Gen Med ; 14: 10351-10372, 2021.
Article in English | MEDLINE | ID: mdl-34992449

ABSTRACT

Over the last few decades, there have been several global outbreaks of severe respiratory infections. The causes of these outbreaks were coronaviruses that had infected birds, mammals and humans. The outbreaks predominantly caused respiratory tract and gastrointestinal tract symptoms and other mild to very severe clinical signs. The current coronavirus disease-2019 (COVID-19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a rapidly spreading illness affecting millions of people worldwide. Among the countries most affected by the disease are the United States of America (USA), India, Brazil, and Russia, with France recording the highest infection, morbidity, and mortality rates. Since early January 2021, thousands of articles have been published on COVID-19. Most of these articles were consistent with the reports on the mode of transmission, spread, duration, and severity of the sickness. Thus, this review comprehensively discusses the most critical aspects of COVID-19, including etiology, epidemiology, pathogenesis, clinical signs, transmission, pathological changes, diagnosis, treatment, prevention and control, and vaccination.

3.
Biomed Res Int ; 2020: 8857428, 2020.
Article in English | MEDLINE | ID: mdl-33381591

ABSTRACT

Angiogenesis is a crucial area in scientific research because it involves many important physiological and pathological processes. Indeed, angiogenesis is critical for normal physiological processes, including wound healing and embryonic development, as well as being a component of many disorders, such as rheumatoid arthritis, obesity, and diabetic retinopathies. Investigations of angiogenic mechanisms require assays that can activate the critical steps of angiogenesis as well as provide a tool for assessing the efficacy of therapeutic agents. Thus, angiogenesis assays are key tools for studying the mechanisms of angiogenesis and identifying the potential therapeutic strategies to modulate neovascularization. However, the regulation of angiogenesis is highly complex and not fully understood. Difficulties in assessing the regulators of angiogenic response have necessitated the development of an alternative approach. In this paper, we review the standard models for the study of tumor angiogenesis on the macroscopic scale that include in vitro, in vivo, and computational models. We also highlight the differences in several modeling approaches and describe key advances in understanding the computational models that contributed to the knowledge base of the field.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Neoplasms/blood supply , Neoplasms/drug therapy , Neovascularization, Pathologic/pathology , Animals , Cell Proliferation , Chick Embryo , Chorioallantoic Membrane , Coculture Techniques , Collagen , Computer Simulation , Drug Combinations , Endothelial Cells/metabolism , Endothelium/metabolism , Human Umbilical Vein Endothelial Cells , Humans , In Vitro Techniques , Laminin , Mice , Models, Theoretical , Proteoglycans , Signal Transduction , Vascular Endothelial Growth Factor A/metabolism , Wound Healing
4.
Drug Des Devel Ther ; 14: 2841-2851, 2020.
Article in English | MEDLINE | ID: mdl-32764883

ABSTRACT

OBJECTIVE: The present study was designed to evaluate the anti-inflammatory effects of different doses of aliskiren in two animal models of inflammation. METHODOLOGY: Sixty-six Wistar rats were allocated into five groups: the first group (six rats) was treated with the vehicle only, without induction of paw edema and granulomatous inflammation, and served as a negative control; the second group (12 rats) was allocated into two subgroups and treated with the vehicle only, with induction of paw edema and granulomatous inflammation, and served as a positive control; the third group (36 rats) was allocated into six subgroups and treated with different doses of aliskiren (15, 30, and 60 mg/kg) in both models; the fourth group (12 rats) was treated with dexamethasone (1 mg/kg) in both models of inflammation. Serum concentrations of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), vascular cell adhesion molecule-1 (VCAM-1), and high sensitivity C-reactive protein (hs-CRP) were measured. Skin samples were also sent for histopathological examination. RESULTS: Aliskiren, in a dose-dependent pattern, significantly decreased inflammation in rat models of inflammation, by attenuating the percentage of exudate, granuloma, and paw edema. Furthermore, it significantly reduced serum concentrations of TNF-α, VCAM-1, and hs-CRP and restored the serum concentration of IL-10. Additionally, significant improvement was seen in the histopathological findings. CONCLUSION: In the current study, aliskiren was successful in decreasing inflammation in both models. These findings suggest that aliskiren is a good candidate for the treatment of inflammatory diseases.


Subject(s)
Amides/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Disease Models, Animal , Fumarates/therapeutic use , Inflammation/drug therapy , Animals , Dose-Response Relationship, Drug , Edema/chemically induced , Edema/drug therapy , Edema/pathology , Female , Formaldehyde , Inflammation/chemically induced , Inflammation/pathology , Male , Rats , Rats, Wistar , Skin/drug effects , Skin/metabolism , Skin/pathology
5.
Int J Nanomedicine ; 15: 2439-2483, 2020.
Article in English | MEDLINE | ID: mdl-32346289

ABSTRACT

Many types of research have distinctly addressed the efficacy of natural plant metabolites used for human consumption both in cell culture and preclinical animal model systems. However, these in vitro and in vivo effects have not been able to be translated for clinical use because of several factors such as inefficient systemic delivery and bioavailability of promising agents that significantly contribute to this disconnection. Over the past decades, extraordinary advances have been made successfully on the development of novel drug delivery systems for encapsulation of plant active metabolites including organic, inorganic and hybrid nanoparticles. The advanced formulas are confirmed to have extraordinary benefits over conventional and previously used systems in the manner of solubility, bioavailability, toxicity, pharmacological activity, stability, distribution, sustained delivery, and both physical and chemical degradation. The current review highlights the development of novel nanocarrier for plant active compounds, their method of preparation, type of active ingredients, and their biomedical applications.


Subject(s)
Biomedical Technology , Drug Delivery Systems , Plant Extracts/administration & dosage , Animals , Drug Carriers/chemistry , Humans , Nanoparticles/chemistry , Nanoparticles/ultrastructure , Solubility
6.
Int J Surg Open ; 26: 125-136, 2020.
Article in English | MEDLINE | ID: mdl-34568614

ABSTRACT

The current rampant coronavirus infection in humans, commonly known as COVID-19, a pandemic that may cause mortality in humans, has been declared a global emergency by the World Health Organization (WHO). The morbidity and mortality rates due to the pandemic are increasing rapidly worldwide, with the USA most affected by the disease. The source COVID-19 is not absolutely clear; however, the disease may be transmitted by either by COVID-19-positive individuals or from a contaminated environment. In this review, we focused on how the COVID-19 virus is transmitted in the community. An extensive literature search was conducted using specific keywords and criteria. Based on the published report, it is concluded that COVID-19 is primarily transmitted human-to-human via oral and respiratory aerosols and droplets with the virus-contaminated environment play a lesser role in the propagation of disease. Healthcare providers and the elderly with comorbidities are especially susceptible to the infection.

7.
Drug Des Devel Ther ; 13: 3321-3329, 2019.
Article in English | MEDLINE | ID: mdl-31571833

ABSTRACT

OBJECTIVE: This study aimed to evaluate the effect of quercetin and/or sitagliptin on testicular damage induced by doxorubicin (DOX). METHODOLOGY: Twenty-five male Wistar rats, weighing 240±20 g, were randomly divided into five groups as follows: a negative control group; that was treated with 1 mL of 0.9% sodium chloride; a DOX-treated group received Intraperitoneal (I.P.) DOX injection (3 mg/kg); a group treated with quercetin 80 mg/kg + sitagliptin 10 mg/kg + DOX; a group treated with quercetin 80 mg/kg + DOX; and a group treated with sitagliptin 10 mg/kg+ DOX. All treatment were given orally daily for 21 days with I.P. DOX 3 mg/kg injection for the treatment groups at days 8, 10, 12, 15, 17, and 19. On day 22, blood was collected for analysis of testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), glutathione peroxidase (GPx), and total antioxidant capacity (TAOC). The testes were also removed and sent for histopathological examination. RESULTS: The study revealed that the combination of quercetin with sitagliptin produced a significant increase in testosterone and FSH levels with a non-significant increase in LH level. This combination also non-significantly decreased the level of ALP and LDH and restored the GPx level with enhancing TAOC. CONCLUSION: The results suggest quercetin/sitagliptin combination as a promising therapeutic modality for attenuation of DOX-induced testicular toxicity in rats, and the main mechanism involved in such effect could be due to the antioxidant and anti-inflammatory properties of both agents.


Subject(s)
Antibiotics, Antineoplastic/toxicity , Doxorubicin/toxicity , Quercetin/pharmacology , Sitagliptin Phosphate/pharmacology , Testis/drug effects , Alkaline Phosphatase/blood , Animals , Antioxidants/metabolism , Follicle Stimulating Hormone/blood , Glutathione Peroxidase/blood , L-Lactate Dehydrogenase/blood , Luteinizing Hormone/blood , Male , Oxidative Stress/drug effects , Rats , Rats, Wistar , Testis/pathology , Testosterone/blood
8.
Int J Nanomedicine ; 10: 1649-66, 2015.
Article in English | MEDLINE | ID: mdl-25767386

ABSTRACT

Cancer nanotherapy is progressing rapidly with the introduction of many innovative drug delivery systems to replace conventional therapy. Although the antitumor activity of zerumbone (ZER) has been reported, there has been no information available on the effect of ZER-loaded nanostructured lipid carrier (NLC) (ZER-NLC) on murine leukemia cells. In this study, the in vitro and in vivo effects of ZER-NLC on murine leukemia induced with WEHI-3B cells were investigated. The results from 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Hoechst 33342, Annexin V, cell cycle, and caspase activity assays showed that the growth of leukemia cells in vitro was inhibited by ZER-NLC. In addition, outcomes of histopathology, transmission electron microscopy, and Tdt-mediated dUTP nick-end labeling analyses revealed that the number of leukemia cells in the spleen of BALB/c leukemia mice significantly decreased after 4 weeks of oral treatment with various doses of ZER-NLC. Western blotting and reverse-transcription quantitative polymerase chain reaction assays confirmed the antileukemia effects of ZER-NLC. In conclusion, ZER-NLC was shown to induce a mitochondrial-dependent apoptotic pathway in murine leukemia. Loading of ZER in NLC did not compromise the anticancer effect of the compound, suggesting ZER-NLC as a promising and effective delivery system for treatment of cancers.


Subject(s)
Antineoplastic Agents , Leukemia/drug therapy , Nanostructures/chemistry , Sesquiterpenes , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Carriers/chemistry , Lipids/chemistry , Mice , Sesquiterpenes/chemistry , Sesquiterpenes/pharmacology , Sesquiterpenes/therapeutic use
9.
Biomed Res Int ; 2014: 563930, 2014.
Article in English | MEDLINE | ID: mdl-25276798

ABSTRACT

Zerumbone- (ZER-) loaded nanostructure lipid carrier (NLC) (ZER-NLC) prepared for its antileukemia effect in vitro was evaluated for its toxicological effects by observing changes in the liver, kidney, spleen, lung, heart, and brain tissues, serum biochemical parameters, total haemogram, and bone marrow stem cells. The acute toxicity study for ZER-NLC was conducted by orally treating BALB/c mice with a single dose with either water, olive oil, ZER, NLC, or ZER-NLC for 14 days. The animals were observed for clinical and behavioral abnormalities, toxicological symptoms, feed consumption, and gross appearance. The liver, kidney, heart, lung, spleen, and brain tissues were assessed histologically. Total haemogram was counted by hemocytometry and microhematocrit reader. Bone marrow examination in terms of cellular morphology was done by Wright staining with bone marrow smear. Furthermore, serum biochemical parameters were determined spectrophotometrically. Grossly all treated mice, their investigated tissues, serum biochemical parameters, total haemogram, and bone marrow were normal. At oral doses of 100 and 200 mg/kg ZER-NLC there was no sign of toxicity or mortality in BALB/c mice. This study suggests that the 50% lethal dose (LD50) of ZER-NLC is higher than 200 mg/kg, thus, safe by oral administration.


Subject(s)
Lipids/toxicity , Nanostructures/toxicity , Sesquiterpenes/toxicity , Administration, Oral , Animals , Body Weight/drug effects , Bone Marrow/drug effects , Bone Marrow/pathology , Hematologic Tests , Mice , Mice, Inbred BALB C , Models, Animal , Organ Size/drug effects , Sesquiterpenes/administration & dosage , Toxicity Tests, Acute
10.
Biomed Res Int ; 2014: 920742, 2014.
Article in English | MEDLINE | ID: mdl-25025076

ABSTRACT

Zerumbone (ZER) is a naturally occurring dietary compound, present in many natural foods consumed today. The compound derived from several plant species of the Zingiberaceae family that has been found to possess multiple biomedical properties, such as antiproliferative, antioxidant, anti-inflammatory, and anticancer activities. However, evidence of efficacy is sparse, pointing to the need for a more systematic review for assessing scientific evidence to support therapeutic claims made for ZER and to identify future research needs. This review provides an updated overview of in vitro and in vivo investigations of ZER, its cancer chemopreventive properties, and mechanisms of action. Therapeutic effects of ZER were found to be scientifically plausible and could be explained partially by in vivo and in vitro pharmacological activities. Much of the research outlined in this paper will serve as a foundation to explain ZER anticancer bioactivity, which will open the door for the development of strategies in the treatment of malignancies using ZER.


Subject(s)
Cell Proliferation/drug effects , Chemoprevention , Neoplasms/drug therapy , Sesquiterpenes/therapeutic use , Antioxidants/administration & dosage , Antioxidants/therapeutic use , Apoptosis/drug effects , Diet , Humans , Neoplasms/pathology , Sesquiterpenes/chemistry , Zingiberaceae/chemistry
11.
Int J Nanomedicine ; 9: 527-38, 2014.
Article in English | MEDLINE | ID: mdl-24549090

ABSTRACT

This investigation evaluated the antileukemia properties of a zerumbone (ZER)-loaded nanostructured lipid carrier (NLC) prepared by hot high-pressure homogenization techniques in an acute human lymphoblastic leukemia (Jurkat) cell line in vitro. The apoptogenic effect of the ZER-NLC on Jurkat cells was determined by fluorescent and electron microscopy, Annexin V-fluorescein isothiocyanate, Tdt-mediated dUTP nick-end labeling assay, cell cycle analysis, and caspase activity. An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) assay showed that ZER-NLC did not have adverse effects on normal human peripheral blood mononuclear cells. ZER-NLC arrested the Jurkat cells at G2/M phase with inactivation of cyclin B1 protein. The study also showed that the antiproliferative effect of ZER-NLC on Jurkat cells is through the intrinsic apoptotic pathway via activation of caspase-3 and caspase-9, release of cytochrome c from the mitochondria into the cytosol, and subsequent cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP). These findings show that the ZER-NLC is a potentially useful treatment for acute lymphoblastic leukemia in humans.


Subject(s)
Antineoplastic Agents/administration & dosage , Leukemia, T-Cell/drug therapy , Nanostructures/administration & dosage , Nanostructures/chemistry , Sesquiterpenes/administration & dosage , Apoptosis/drug effects , Caspases/metabolism , DNA Fragmentation/drug effects , Drug Carriers/chemistry , Drug Delivery Systems , G2 Phase Cell Cycle Checkpoints/drug effects , Humans , Jurkat Cells , Leukemia, T-Cell/metabolism , Leukemia, T-Cell/pathology , Lipids/chemistry , Mitochondria/drug effects , Mitochondria/metabolism , Models, Biological , Nanomedicine , Nanostructures/ultrastructure
12.
Article in English | MEDLINE | ID: mdl-24516503

ABSTRACT

The edible seaweed Sargassum polycystum (SP) is traditionally used against several human diseases. This investigation evaluated the effects of two dietary doses of SP ethanolic and aqueous extracts on the pancreatic, hepatic, and renal morphology of type 2 diabetic rats (T2DM). T2DM was induced by feeding rats on high calorie diet followed by a low dose streptozotocin. Changes in the diabetic rat organs in SP treated groups with different doses of extracts were compared with normal rats, diabetic control rats, and metformin treated rats. After 22 days of treatment, the pathological lesions of the livers and kidneys in the diabetic rats were quantitatively and qualitatively alleviated (P < 0.05) by both the SP extracts at 150 mg/kg body weight and by metformin. All the treated diabetic groups revealed marked improvement in the histopathology of the pancreas compared with the control diabetic group. Oral administration of 300 mg/kg body weight of aqueous and ethanolic extracts of SP and metformin revealed pancreas protective or restorative effects. The seaweed extracts at 150 mg/kg body weight reduced the liver and kidney damages in the diabetic rats and may exert tissue repair or restoration of the pancreatic islets in experimentally induced diabetes to produce the beneficial homeostatic effects.

13.
Nat Prod Commun ; 9(9): 1237-42, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25918781

ABSTRACT

This investigation determined the anticancer properties of zerumbone (ZER) on the human T-cell (Jurkat) line using the MTT assay, microscopic evaluations, flow cytometric analyses, and caspase activity estimations. The results showed that ZER is selectively cytotoxic to Jurkat cells in a dose and time-dependent manner with IC50 of 11.9 ± 0.2, 8.6 ± 0.5 and 5.4 ± 0.4 µg/mL at 24, 48 and 72 hours of treatment, respectively. ZER did not produce an adverse effect on normal human peripheral blood mononuclear cells (PBMC). ZER is not as cytotoxic as doxorubicin, which imposed an inhibitory effect on Jurkat cells with IC50 of 2.1 ± 0.2, 1.8 ± 0.15, 1.5 ± 0.07 µg/mL after 24, 48 and 72 hours treatment, respectively. ZER significantly (P < 0.05) arrested Jurkat cells at the G2/M phase of the cell cycle. The antiproliferative effect of ZER on Jurkat cells was through the apoptotic intrinsic pathway via the activation of caspase-3 and -9. The results showed that ZER can be further developed into a safe chemotherapeutic compound for the treatment of cancers, especially leukemia.


Subject(s)
Apoptosis/drug effects , G2 Phase Cell Cycle Checkpoints/drug effects , Leukemia/physiopathology , M Phase Cell Cycle Checkpoints/drug effects , Mitochondria/drug effects , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology , Zingiberales/chemistry , Humans , Jurkat Cells , Mitochondria/metabolism
14.
Int J Nanomedicine ; 8: 2769-81, 2013.
Article in English | MEDLINE | ID: mdl-23946649

ABSTRACT

Zerumbone, a natural dietary lipophilic compound with low water solubility (1.296 mg/L at 25°C) was used in this investigation. The zerumbone was loaded into nanostructured lipid carriers using a hot, high-pressure homogenization technique. The physicochemical properties of the zerumbone-loaded nanostructured lipid carriers (ZER-NLC) were determined. The ZER-NLC particles had an average size of 52.68 ± 0.1 nm and a polydispersity index of 0.29 ± 0.004 µm. Transmission electron microscopy showed that the particles were spherical in shape. The zeta potential of the ZER-NLC was -25.03 ± 1.24 mV, entrapment efficiency was 99.03%, and drug loading was 7.92%. In vitro drug release of zerumbone from ZER-NLC was 46.7%, and for a pure zerumbone dispersion was 90.5% over 48 hours, following a zero equation. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in human T-cell acute lymphoblastic leukemia (Jurkat) cells, the half maximal inhibitory concentration (IC50) of ZER-NLC was 5.64 ± 0.38 µg/mL, and for free zerumbone was 5.39 ± 0.43 µg/mL after 72 hours of treatment. This study strongly suggests that ZER-NLC have potential as a sustained-release drug carrier system for the treatment of leukemia.


Subject(s)
Antineoplastic Agents/chemistry , Drug Carriers/chemistry , Lipids/chemistry , Nanoparticles/chemistry , Sesquiterpenes/chemistry , Analysis of Variance , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Cell Survival/drug effects , Crystallization , Drug Carriers/pharmacokinetics , Drug Carriers/pharmacology , Drug Stability , Humans , Hydrogen-Ion Concentration , Jurkat Cells , Leukemia , Lipids/pharmacokinetics , Lipids/pharmacology , Microbial Sensitivity Tests , Particle Size , Sesquiterpenes/pharmacokinetics , Sesquiterpenes/pharmacology , X-Ray Diffraction
15.
Nutr Cancer ; 65(2): 255-62, 2013.
Article in English | MEDLINE | ID: mdl-23441613

ABSTRACT

The tropical edible red seaweed (Eucheuma cottonii L.) is rich in nutrients and polyphenolic compounds that may suppress cancer through its antioxidant and antiproliferative properties. The study reports on rat mammary tumor suppression and tissue antioxidant status modulation by E. cottonii ethanol extract (ECE). The effect of orally administered ECE (100 mg/kg body-weight) was compared with that of tamoxifen (10 mg/kg body-weight). Rat was induced to develop mammary tumor with subcutaneous injection of LA-7 cells (6 × 10(6) cells/rat). The ECE was more effective than tamoxifen in suppressing tumor growth (27%), improving tissues (plasma, liver, and kidney) malondialdehyde concentrations, superoxide dismutase activity and erythrocyte glutathione concentrations (P < 0.05). Unlike tamoxifen, the ECE displayed little toxicity to the liver and kidneys. The ECE exhibited strong anticancer effect with enzyme modulating properties, suggesting its potential as a suppressing agent for mammary gland tumor.


Subject(s)
Mammary Neoplasms, Experimental/drug therapy , Plant Extracts/pharmacology , Rhodophyta , Seaweed , Tamoxifen/pharmacology , Administration, Oral , Animals , Antineoplastic Agents, Hormonal/pharmacology , Antineoplastic Agents, Phytogenic/adverse effects , Antineoplastic Agents, Phytogenic/pharmacology , Drug Screening Assays, Antitumor/methods , Female , Kidney/drug effects , Kidney/metabolism , Liver/drug effects , Liver/metabolism , Malondialdehyde/metabolism , Mammary Neoplasms, Experimental/pathology , Rats , Rats, Sprague-Dawley , Superoxide Dismutase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...